Clinical Trial

Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

Study acronym: ASPIRE
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Protocol Amendment History 1 change
notable Trial sites expanded: 184 -> 187 locations 2026-05-09
Trial Details
NCT Number NCT03907046
Lead Sponsor Yale University
Collaborators: National Institute of Neurological Disorders and Stroke (NINDS)
Conditions Intracerebral Hemorrhage, Atrial Fibrillation
Enrollment 700 participants
Start Date 2020-01-28
Primary Completion 2027-04 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2026-05-08